TICKERNERD
Menu
LUNGLUNGHealthcare · Medical Devices

LUNG Stock Forecast: Pulmonx Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.86
+0.54% on the day

The 5 Wall Street analysts covering Pulmonx Corp. hold a median 12-month price target of $3 — +61.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$79.9M
Ticker Nerd rank
82 / 100
Median analyst target
$3.00
Analysts covering
5
Revenue$22.8M−4.6% y/y
Operating income−$9.1M
Net income−$10.1M
Free cash flow−$5.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−17.7%
1M
−17.7%
YTD
−15.8%
1Y
+10.1%
From 52W high
−28.5%
From 52W low
+59.0%
$1.17
$2.60
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LUNG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pulmonx Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
82 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
87
Revisions
85
Accruals
82
Size
78
Issuance
56
Momentum
56
Quality
45
Value
36
Volatility
21

Growth (87): Sales and profits are climbing, and climbing faster than before.

Volatility (21): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LUNG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LUNG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26LUNGHigh $5.00Median $3.00Low $2.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
3 Buy2 Hold0 Sell
Low $2.50Median $3.00High $5.00

The green dot is the last close — the median target sits +61.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
30 Apr 2026D. Boral CapitalMaintainsBuy—
30 Apr 2026D. Boral CapitalMaintainsBuy$14
5 Mar 2026Canaccord GenuityMaintainsBuy—
5 Mar 2026D. Boral CapitalMaintainsBuy—
20 Feb 2026D. Boral CapitalMaintainsBuy—
13 Nov 2025D. Boral CapitalMaintainsBuy—
28 Oct 2025D. Boral CapitalMaintainsBuy—
28 Oct 2025Lake StreetMaintainsBuy—
8 Sept 2025D. Boral CapitalMaintainsBuy—
1 Aug 2025Wells FargoMaintainsEqual-Weight—
31 July 2025D. Boral CapitalMaintainsBuy—
31 July 2025Lake StreetMaintainsBuy—
31 July 2025Piper SandlerDowngradeNeutral—
31 July 2025StifelMaintainsBuy—
22 May 2025CitigroupMaintainsNeutral—
1 May 2025Canaccord GenuityMaintainsBuy—
1 May 2025D. Boral CapitalMaintainsBuy—
1 May 2025Piper SandlerReiteratesOverweight—
11 Mar 2025D. Boral CapitalMaintainsBuy—
10 Mar 2025D. Boral CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LUNG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LUNG vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Pulmonx Corp. returned +10.1% against +17.5% for the S&P 500, dividends included.

LUNG vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Oct 25Jan 26Apr 26Jul 26LUNGS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LUNG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Pulmonx Corp. (LUNG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.4×

Cheaper than 83% of US stocks

Price / sales
0.9×

Cheaper than 72% of US stocks

Price / book
2.0×

Cheaper than 45% of US stocks

EV / EBITDA
−1.8×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
−4.6%

Higher than 20% of US stocks

Earnings growth (YoY)
—
Gross margin
78.0%

Higher than 89% of US stocks

Operating margin
−39.8%

Higher than 18% of US stocks

Net margin
−55.0%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−88.9%

Higher than 15% of US stocks

Return on assets
−22.1%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Pulmonx Corp. (LUNG) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pulmonx Corp. has a market value of $79.9M and an enterprise value of $79.8M.

  • Revenue in the twelve months to 30 June 2026: $87.4M. The latest quarter shrank 4.6% year on year.

  • Net income over the same four quarters: −$48.1M, a −55.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.16.

  • Free cash flow in the twelve months to 30 June 2026: −$30.7M.

  • Shares outstanding: 42.9M.

  • Trailing P/E: −1.4×; forward P/E: −2.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Pulmonx Corp. employs 296 people — $295K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

LUNG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
LUNGPulmonx Corp.$79.9M
82
CVRXCVRx, Inc.$75.8M
33
SERASera Prognostics, Inc.$79.5M
41
HYPRHyperfine, Inc.$83.8M
50
ECORelectroCore, Inc.$86.7M
59
LNSRLENSAR, Inc.$90.7M
62
RPIDRapid Micro Biosystems, Inc.$61.3M
28

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pulmonx Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LUNG news & analysis

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 1 Sept 2026neutral

Pulmonx Corporation granted equity awards under its 2025 Inducement Plan to four individuals hired in the third fiscal quarter of 2026. The awards, approved by the Compensation Committee, were issued as an inducement for the new employees' employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — This is a routine corporate announcement regarding employee inducement equity grants, providing visibility into Pulmonx's hiring and compensation activity without signaling company performance.

Pulmonx to Participate in Upcoming Investor Conferences

GlobeNewsWire · 27 Aug 2026neutral

Pulmonx Corporation announced that its management will participate in several upcoming investor conferences. The company, a global leader in minimally invasive treatments for severe lung disease, shared the news on August 27, 2026.

Why it matters — Investor conference appearances give LUNG watchers opportunities to hear directly from management about the company's business, though the announcement itself carries no financial details.

Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?

Zacks Investment Research · 26 Aug 2026positive

According to Zacks Investment Research, Pulmonx Corp. (LUNG) experienced a "golden cross" event in which its 50-day simple moving average broke above its 200-day simple moving average after reaching an important support level. The item frames this as a potentially favorable technical development for the stock.

Why it matters — A LUNG watcher would care because the golden cross is a widely followed technical signal that can indicate a shift in the stock's short- and long-term price trend.

Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year

MarketBeat · 15 Aug 2026positive

Pulmonx is rebuilding its sales organization to return to growth, and CEO Glen French said during a Canaccord fireside chat that the company is preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year.

Why it matters — A LUNG watcher would care because the company's sales-force rebuild and planned international AeriSeal commercialization signal near-term strategic moves that could affect revenue and pipeline progress.

What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?

Zacks Investment Research · 14 Aug 2026neutral

Zacks Investment Research published an article examining whether Pulmonx Corporation (LUNG) qualifies as a strong momentum stock pick. The piece evaluates the company's characteristics for momentum investors.

Why it matters — The article signals that analysts are assessing LUNG's momentum profile, which could influence investor attention on the stock.

FAQ

Frequently asked questions about LUNG stock

What is the LUNG stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Pulmonx Corp. have a median 12-month price target of $3, with estimates ranging from $2.5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LUNG stock a buy right now?

Of the 5 analysts covering Pulmonx Corp., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pulmonx Corp. 82 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LUNG?

As at 12 Sept 2026, Pulmonx Corp. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).

Will LUNG stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +61.3% from the last close, and Ticker Nerd's factor model ranks Pulmonx Corp. 82 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LUNG stock forecast for 2030?

No analyst covering Pulmonx Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LUNG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $5 over the next 12 months.

How has LUNG stock performed over the past year?

Pulmonx Corp. returned +10.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pulmonx Corp. do?

Pulmonx Corporation is a medical technology company focused on minimally invasive treatments for severe emphysema and other obstructive lung diseases. The company’s core offering is the Zephyr Endobronchial Valve, a bronchoscopic implant designed to reduce lung hyperinflation in patients who are not candidates for, or do not want, surgery.

What is the latest news on LUNG?

The most recent item we track (GlobeNewsWire, 1 Sept 2026): "Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Pulmonx Corporation granted equity awards under its 2025 Inducement Plan to four individuals hired in the third fiscal quarter of 2026. The awards, approved by the Compensation Committee, were issued as an inducement for the new employees' employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Company

About Pulmonx Corp.

Pulmonx Corporation is a medical technology company focused on minimally invasive treatments for severe emphysema and other obstructive lung diseases. The company’s core offering is the Zephyr Endobronchial Valve, a bronchoscopic implant designed to reduce lung hyperinflation in patients who are not candidates for, or do not want, surgery. Pulmonx also provides the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform, which support patient evaluation, treatment planning, and clinical decision-making. Its products are used primarily by hospitals and specialty pulmonary centers within interventional pulmonology. Pulmonx serves a global clinical market and positions its portfolio around evidence-based tools that help physicians identify appropriate patients and deliver targeted lung-volume reduction therapy.

CEO Mr. Glendon E. French · 296 employees · United States · https://pulmonx.com